MDT vs TMDX
MDT: Medtronic is a global healthcare technology leader dedicated to alleviating pain, restoring health, and extending life through innovative medical devices and digital solutions. TMDX: TransMedics is a medical technology company providing a portable organ perfusion system designed to optimize the quality and availability of donor organs for transplant.
Side-by-side fundamentals
| Metric | MDT | TMDX | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $94.63 | $74.75 | |
| Market cap | $121.0B | $2.6B | |
| P/E as of 2026-10-20 | 23.31 | 19.37 | TMDX lower |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2026 | 2.39 | n/a | |
| Net margin | +13.2% | +31.4% | TMDX higher |
| Gross margin FY2025, SEC XBRL | n/a | +59.9% | |
| Operating margin | +17.8% | +17.9% | TMDX higher |
| ROE | +9.7% | +40.2% | TMDX higher |
| ROA | +5.2% | +17.8% | TMDX higher |
| Debt / equity filed borrowings incl. finance leases, balance sheet 2026-07-31 | 0.56 | n/a | |
| Revenue growth (YoY) | +8.4% | +37.1% | TMDX higher |
| Revenue CAGR (3y) SEC XBRL | +5.2% | +86.4% | TMDX higher |
| Dividend yield as of 2026-09-03 | +3.1% | n/a | |
| Dividend streak (yrs) SEC XBRL | 14 | 0 | MDT higher |
| Beta as of 2026-09-03 | 0.35 | 1.18 | |
| 1-year return as of 2026-10-20 close | -1.3% | -37.7% | MDT higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.